22 results on '"Gandhi, Ashu"'
Search Results
2. Population-based germline testing of BRCA1, BRCA2, and PALB2 in breast cancer patients in the United Kingdom: Evidence to support extended testing, and definition of groups who may not require testing
- Author
-
Evans, D. Gareth, Woodward, Emma R., Burghel, George J., Allen, Sophie, Torr, Beth, Hamill, Monica, Kavanaugh, Grace, Hubank, Mike, Bremner, Stephen, Jones, Christopher I., Schlecht, Helene, Astley, Susan, Bowers, Sarah, Gibbons, Sarah, Ruane, Helen, Fosbury, Caroline, Howell, Sacha J., Forde, Claire, Lalloo, Fiona, Newman, William G., Smith, Miriam J., Howell, Anthony, Turnbull, Clare, and Gandhi, Ashu
- Published
- 2024
- Full Text
- View/download PDF
3. Abemaciclib Therapy Using the MonarchE Criteria Results in Large Numbers of Excess Axillary Node Clearances—Time to Pause and Reflect?
- Author
-
Ahari, Daniel, Wilkinson, Mark, Ali, Nisha, Taxiarchi, Vicky P., Dave, Rajiv V., and Gandhi, Ashu
- Subjects
THERAPEUTIC use of antineoplastic agents ,LYMPHEDEMA ,RISK assessment ,HORMONE receptor positive breast cancer ,AXILLARY lymph node dissection ,LONGITUDINAL method ,DISEASES ,WOMEN'S health ,CYCLIN-dependent kinases ,DISEASE risk factors ,CHEMICAL inhibitors - Abstract
Simple Summary: Abemaciclib is an important addition to the care of women with hormone receptor-positive breast cancer. To qualify for abemaciclib treatment, some women are advised to undergo axillary node clearance surgery as finding more than three axillary nodes with metastatic cancer allows access to abemaciclib. This paper explores the balance between the benefits of axillary node clearance in permitting access to abemaciclib and the harms of surgery. We examine how many women need to undergo axillary node clearance before one woman clinically benefits from the procedure. We show that for every 10 women undergoing axillary node clearance surgery, only one eventually qualifies for abemaciclib. The remaining nine would have axillary surgery but still not qualify for abemaciclib as less than four metastatic axillary nodes are found despite full axillary clearance. However, these women could still suffer the complications of axillary node clearance surgery. The monarchE study added the CDK4/6 inhibitor abemaciclib to the care of women with oestrogen-positive (ER+) breast cancers. Eligibility required meeting monarchE criteria—either >3 positive axillary nodes, or 1–3 positive sentinel nodes (SNB+) with tumour size >50 mm or grade 3 cancers. Women were advised to proceed to completion axillary node clearance (cANC) if size/grade criteria were not fulfilled for >3 positive nodes to be identified. However, cANC is associated with significant morbidity, conflicting with the potential benefits of abemaciclib. We analysed data of 229 consecutive women (2016-2022) with ER+ breast cancer and SNB+ who proceeded to cANC, keeping with contemporary treatment guidelines. We used this cohort to assess numbers that, under national guidance in place currently, would be advised to undergo cANC solely to check eligibility for abemaciclib treatment. Using monarchE criteria, 90 women (39%) would have accessed abemaciclib based on SNB+ and size/grade, without cANC. In total, 139 women would have been advised to proceed to cANC to check eligibility, with only 15/139 (11%) having >3 positive nodes after sentinel node biopsy and cANC. The remaining 124 (89%) would have undergone cANC but remained ineligible for abemaciclib. Size, age, grade, and Ki67 did not predict >3 nodes at cANC. Following cANC, a large majority of women with ER+, <50 mm, and grade 1–2 tumours remain ineligible for abemaciclib yet are subject to significant morbidity including lifelong lymphoedema risk. The monarchE authors state that 15 women need abemaciclib therapy for 1 to clinically benefit. Thus, in our cohort, 139 women undergoing cANC would lead to one woman benefitting. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the administration of repetitive transcranial magnetic stimulation.
- Author
-
Hussain, Salam, Chamoli, Suneel, Fitzgerald, Paul, Gandhi, Ashu, Gill, Shane, Sarma, Shanthi, and Loo, Colleen
- Subjects
MEDICAL protocols ,CONSENSUS (Social sciences) ,PSYCHIATRISTS ,PROFESSIONAL practice ,PSYCHIATRY ,PROFESSIONAL associations ,MEDICAL societies ,HEALTH promotion ,EVIDENCE-based medicine ,DISEASE relapse ,TRANSCRANIAL magnetic stimulation ,MEDICAL practice ,MEDICAL referrals ,PSYCHOSOCIAL factors - Abstract
Objectives: To provide guidance for the optimal administration of repetitive transcranial magnetic stimulation, based on scientific evidence and supplemented by expert clinical consensus. Methods: Articles and information were sourced from existing guidelines and published literature. The findings were then formulated into consensus-based recommendations and guidance by the authors. The guidelines were subjected to rigorous successive consultation within the RANZCP, involving the Section of ECT and Neurostimulation (SEN) Committee, its broader membership and expert committees. Results: The RANZCP professional practice guidelines (PPG) for the administration of rTMS provide up-to-date advice regarding the use of rTMS in clinical practice. The guidelines are intended for use by psychiatrists and non-psychiatrists engaged in the administration of rTMS to facilitate best practice to optimise outcomes for patients. The guidelines strive to find the appropriate balance between promoting best evidence-based practice and acknowledging that evidence for rTMS use is a continually evolving. Conclusion: The guidelines provide up-to-date advice for psychiatrists and non-psychiatrists to promote optimal standards of rTMS practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women
- Author
-
Evans, D. Gareth, Howell, Sacha J., Gandhi, Ashu, van Veen, Elke M., Woodward, Emma R., Harvey, James, Barr, Lester, Wallace, Andrew, Lalloo, Fiona, Wilson, Mary, Hurley, Emma, Lim, Yit, Maxwell, Anthony J., Harkness, Elaine F., and Howell, Anthony
- Published
- 2021
- Full Text
- View/download PDF
6. Biological and synthetic mesh assisted breast reconstruction procedures: Joint guidelines from the Association of Breast Surgery and the British Association of Plastic, Reconstructive and Aesthetic Surgeons
- Author
-
Whisker, Lisa, Barber, Matthew, Egbeare, Donna, Gandhi, Ashu, Gilmour, Adam, Harvey, James, Martin, Lee, Tillett, Rachel, and Potter, Shelley
- Published
- 2021
- Full Text
- View/download PDF
7. Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.
- Author
-
Tsoulaki, Olga, Tischkowitz, Marc, Antoniou, Antonis C., Musgrave, Hannah, Rea, Gillian, Gandhi, Ashu, Cox, Karina, Irvine, Tracey, Holcombe, Sue, Eccles, Diana, Turnbull, Clare, Cutress, Ramsey, Andreou, Avgi, Badran, Abdul, Bartlett, Marion, Berlin, Cheryl, Binysh, Kathie, Brennan, Paul, Cleaver, Ruth, and Corbett, Gemma
- Abstract
Background: The CanRisk tool, which operationalises the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is used by Clinical Geneticists, Genetic Counsellors, Breast Oncologists, Surgeons and Family History Nurses for breast cancer risk assessments both nationally and internationally. There are currently no guidelines with respect to the day-to-day clinical application of CanRisk and differing inputs to the model can result in different recommendations for practice. Methods: To address this gap, the UK Cancer Genetics Group in collaboration with the Association of Breast Surgery and the CanGene-CanVar programme held a workshop on 16
th of May 2023, with the aim of establishing best practice guidelines. Results: Using a pre-workshop survey followed by structured discussion and in-meeting polling, we achieved consensus for UK best practice in use of CanRisk in making recommendations for breast cancer surveillance, eligibility for genetic testing and the input of available information to undertake an individualised risk assessment. Conclusions: Whilst consensus recommendations were achieved, the meeting highlighted some of the barriers limiting the use of CanRisk in clinical practice and identified areas that require further work and collaboration with relevant national bodies and policy makers to incorporate wider use of CanRisk into routine breast cancer risk assessments. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
8. Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400.
- Author
-
Woodward, Emma R., Lalloo, Fiona, Forde, Claire, Pugh, Sarah, Burghel, George J., Schlecht, Helene, Harkness, Elaine F., Howell, Anthony, Howell, Sacha J., Gandhi, Ashu, and Evans, D. Gareth
- Abstract
Background The identification of germline pathogenic gene variants (PGVs) in triple negative breast cancer (TNBC) is important to inform further primary cancer risk reduction and TNBC treatment strategies. We therefore investigated the contribution of breast cancer associated PGVs to familial and isolated invasive TNBC. Methods Outcomes of germline BRCA1, BRCA2 and CHEK2_c.1100delC testing were recorded in 1514 women (743--isolated, 771--familial), and for PALB2 in 846 women (541--isolated, 305--familial), with TNBC and smaller numbers for additional genes. Breast cancer free controls were identified from Predicting Risk Of Cancer At Screening and BRIDGES (Breast cancer RIsk after Diagnostic GEne Sequencing) studies. Results BRCA1_PGVs were detected in 52 isolated (7.0%) and 195 (25.3%) familial cases (isolated--OR=58.9, 95% CI: 16.6 to 247.0), BRCA2_PGVs in 21 (2.8%) isolated and 67 (8.7%) familial cases (isolated--OR=5.0, 95% CI: 2.3 to 11.2), PALB2_PGVs in 9 (1.7%) isolated and 12 (3.9%) familial cases (isolated--OR=8.8, 95% CI: 2.5 to 30.4) and CHEK2_c.1100delC in 0 isolated and 3 (0.45%) familial cases (isolated--OR=0.0, 95% CI: 0.00 to 2.11). BRCA1_PGV detection rate was >10% for all familial TNBC age groups and significantly higher for younger diagnoses (familial: <50 years, n=165/538 (30.7%); =50 years, n=30/233 (12.9%); p<0.0001). Women with a G3_TNBC were more likely to have a BRCA1_PGV as compared with a BRCA2 or PALB2_PGV (p<0.0001). 0/743 isolated TNBC had the CHEK2_c.1100delC PGV and 0/305 any ATM_PGV, but 2/240 (0.83%) had a RAD51D_PGV. Conclusion PGVs in BRCA1 are associated with G3_ TNBCs. Familial TNBCs and isolated TNBCs <30 years have a >10% likelihood of a PGV in BRCA1. BRCA1_ PGVs are associated with younger age of familial TNBC. There was no evidence for any increased risk of TNBC with CHEK2 or ATM PGVs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer
- Author
-
Basu, Narendra Nath, Hodson, James, Chatterjee, Shaunak, Gandhi, Ashu, Wisely, Julie, Harvey, James, Highton, Lyndsey, Murphy, John, Barnes, Nicola, Johnson, Richard, Barr, Lester, Kirwan, Cliona C., Howell, Sacha, Baildam, Andrew D., Howell, Anthony, and Evans, D. Gareth
- Published
- 2021
- Full Text
- View/download PDF
10. Electroconvulsive Therapy Credentialing for Psychiatrists—Review of Required Standards Across States and Territories in Australia.
- Author
-
Purushothaman, Subramanian, Simpson, Brett, Hussain, Salam, Loo, Colleen K., Gill, Shane, Chamoli, Suneel, Weiss, Alan, Sarma, Shanthi, Fitzgerald, Paul B., Fasnacht, Matthew, and Gandhi, Ashu
- Published
- 2024
- Full Text
- View/download PDF
11. Mastitis and Mammary Abscess Management Audit (MAMMA) in the UK and Ireland.
- Author
-
Courtney, Alona, Clymo, Jonathon, Parks, Ruth, Wilkins, Alexander, Brown, Ruth, O'Connell, Rachel, Dave, Rajiv, Dillon, Marianne, Fatayer, Hiba, Gallimore, Rachel, Gandhi, Ashu, Gardiner, Matthew, Harmer, Victoria, Hookway, Lyndsey, Irwin, Gareth, Ives, Charlotte, Mathers, Helen, Murray, Juliette, O'Leary, D Peter, and Patani, Neill
- Subjects
MASTITIS ,ABSCESSES ,SURGICAL site ,SURGICAL drainage ,HOSPITAL patients ,NEEDLE biopsy ,NEEDLES & pins ,NEEDLESTICK injuries - Abstract
Background: The aim of this multicentre prospective audit was to describe the current practice in the management of mastitis and breast abscesses in the UK and Ireland, with a specific focus on rates of surgical intervention. Methods: This audit was conducted in two phases from August 2020 to August 2021; a phase 1 practice survey and a phase 2 prospective audit. Primary outcome measurements for phase 2 included patient management pathway characteristics and treatment type (medical/radiological/surgical). Results: A total of 69 hospitals participated in phase 2 (1312 patients). The key findings were a high overall rate of incision and drainage (21.0 per cent) and a lower than anticipated proportion of ultrasound-guided aspiration of breast abscesses (61.0 per cent). Significant variations were observed regarding the rate of incision and drainage (range 0–100 per cent; P < 0.001) and the rate of needle aspiration (range 12.5–100 per cent; P < 0.001) between individual units. Overall, 22.5 per cent of patients were admitted for inpatient treatment, out of whom which 72.9 per cent were commenced on intravenous antibiotics. The odds of undergoing incision and drainage for a breast abscess or being admitted for inpatient treatment were significantly higher if patients presented at the weekend compared with a weekday (P ≤ 0.023). Breast specialists reviewed 40.9 per cent of all patients directly, despite the majority of patients (74.2 per cent) presenting within working hours on weekdays. Conclusions: Variation in practice exists in the management of mastitis and breast abscesses, with high rates of incision and drainage in certain regions of the UK. There is an urgent need for a national best-practice toolbox to minimize practice variation and standardize patient care. The Mastitis and Mammary Abscess Management Audit (MAMMA) is the first international audit, conducted in 69 hospitals across the UK and Ireland, involving contemporaneous data capture on the presentation and management of 1312 patients with mastitis and breast abscess. Key results included a substantial inpatient admission rate (22.5 per cent), a high overall rate of surgical incision and drainage (21.0 per cent), and a comparatively low use of ultrasound-guided aspiration (61.0 per cent). The data also identified significantly increased odds of undergoing incision and drainage for a breast abscess or being admitted for inpatient treatment, if patients presented at the weekend compared with on a weekday. Lay Summary: Mastitis and breast abscess is a painful infection of the breast. It is an extremely common breast problem. One in three women can get this condition at some stage in their life. To treat a breast abscess, the pus inside should be drained out of the body. This can be done either by cutting into the breast using surgery or by inserting a fine needle using an ultrasonography scan (which uses ultrasound). Fine-needle drainage has the benefit that it does not require admission to hospital. Surgery can cause the breast to look misshapen. It is unknown which method is used more often in the UK and Ireland. The aim of this study was to describe how mastitis and breast abscesses are treated in the UK and Ireland. This study involved a survey of practice (phase 1) and collection of data, which are routinely recorded for these patients (phase 2). This study involved 69 hospitals and 1312 patient records. One in five women had an operation for a breast abscess. This was higher than expected. Six in 10 women had a pus drainage using a fine needle. The chance of having an operation depended on the hospital. Women that came to hospital at the weekend were almost twice as likely to have an operation. One in five women were admitted to hospital. The chances of that more than doubled if a woman came to hospital at the weekend. There are differences in treatment of mastitis and breast abscesses across the UK and Ireland. Changes need to be put in place to make access to treatment more equal. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Detection of pathogenic variants in breast cancer susceptibility genes in bilateral breast cancer.
- Author
-
Evans, D. Gareth, Burghel, George J., Schlecht, Helene, Harkness, Elaine F., Gandhi, Ashu, Howell, Sacha J., Howell, Anthony, Forde, Claire, Lalloo, Fiona, Newman, William G., Smith, Miriam Jane, and Woodward, Emma Roisin
- Abstract
Purpose To investigate the frequency of germline pathogenic variants (PVs) in women with bilateral breast cancer. Methods We undertook BRCA1/2 and CHEK2 c.1100delC molecular analysis in 764 samples and a multigene panel in 156. Detection rates were assessed by age at first primary, Manchester Score, and breast pathology. Oestrogen receptor (ER) status of the contralateral versus first breast cancer was compared on 1081 patients with breast cancer with BRCA1IBRCA2 PVs. Results 764 women with bilateral breast cancer have undergone testing of BRCA1/2 and CHEK2; 407 were also tested for PALB2 and 177 for ATM. Detection rates were BRCA1 11.6%, BRCA2 14.0%, CHEK2 2.4%, PALB2 1.0%, ATM 1.1% and, for a subset of mainly very early onset tumours, TP53 4.6% (9 of 195). The highest PV detection rates were for triple negative cancers for BRCA1 (26.4%), grade 3 ER+HER2 for BRCA2 (27.9%) and HER2+ for CHEK2 (8.9%). ER status of the first primary in BRCA1 and BRCA2 PV heterozygotes was strongly predictive of the ER status of the second contralateral tumour since ~90% of second tumours were ER- in BRCA1 heterozygotes, and 50% were ERin BRCA2 heterozygotes if the first was ER-. Conclusion We have shown a high rate of detection of BRCA1 and BRCA2 PVs in triple negative and grade 3 ER+HER2- first primary diagnoses, respectively. High rates of HER2+ were associated with CHEK2 PVs, and women ≤30 years were associated with TP53 PVs. First primary ER status in BRCA1/2 strongly predicts the second tumour will be the same ER status even if unusual for PVs in that gene. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Prescribing electroconvulsive therapy for depression: Not as simple as it used to be.
- Author
-
Gill, Shane, Hussain, Salam, Purushothaman, Subramanian, Sarma, Shanthi, Weiss, Alan, Chamoli, Suneel, Fasnacht, Matthew, Gandhi, Ashu, Fitzgerald, Paul B, Simpson, Brett, and Loo, Colleen K
- Subjects
PROFESSIONS ,ELECTROCONVULSIVE therapy ,COGNITION ,TREATMENT effectiveness ,MENTAL depression ,DRUGS ,SEIZURES (Medicine) ,PULSE (Heart beat) - Abstract
In the last century, prescribing electroconvulsive therapy usually involved considering the relative merits of unilateral versus bilateral electroconvulsive therapy, with most other parameters fixed. However, research over the last 30 years has discovered that several parameters of the electroconvulsive therapy stimulus can have a significant impact on efficacy and cognitive side effects. The stimulus dose relative to seizure threshold was shown to significantly affect efficacy, especially for right unilateral electroconvulsive therapy, where suprathreshold doses in the vicinity of 5–6 times seizure threshold were far more efficacious than doses closer to threshold. However, this did not hold for bitemporal electroconvulsive therapy, where near-threshold stimuli were equally effective as suprathreshold stimuli. Then, changes in stimulus pulse width were found to also have a significant impact on both efficacy and side effects, with ultrabrief pulse widths of 0.3 ms having significantly fewer cognitive side effects in unilateral electroconvulsive therapy than standard brief pulse widths of 1.0 ms, with only slightly reduced efficacy. Therefore, choosing the optimum electroconvulsive therapy prescription for an individual patient now requires consideration of placement, pulse width and stimulus dose relative to seizure threshold, and how these three interact with each other. This viewpoint aims to raise awareness of these issues for psychiatrists involved in electroconvulsive therapy practice. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Differential involvement of germline pathogenic variants in breast cancer genes between DCIS and low-grade invasive cancers.
- Author
-
Evans, D. Gareth, Sithambaram, Siva, van Veen, Elke Maria, Burghel, George J., Schlecht, Helene, Harkness, Elaine F., Byers, Helen, Ellingford, Jamie M., Gandhi, Ashu, Howel, Sacha J., Howel, Anthony, Forde, Claire, Lalloo, Fiona, Newman, William G., Smith, Miriam Jane, and Woodward, Emma Roisin
- Abstract
Purpose To investigate frequency of germline pathogenic variants (PVs) in women with ductal carcinoma in situ (DCIS) and grade 1 invasive breast cancer (G1BC). Methods We undertook BRCA1/2 analysis in 311 women with DCIS and 392 with G1BC and extended panel testing (non-BRCA1/2) in 176/311 with DCIS and 156/392 with G1BC. We investigated PV detection by age at diagnosis, Manchester Score (MS), DCIS grade and receptor status. Results 30/311 (9.6%) with DCIS and 16/392 with G1BC (4.1%) had a BRCA1/2 PV (p=0.003), and 24/176-(13.6%) and 7/156-(4.5%), respectively, a non-BRCA1/2 PV (p=0.004). Increasing MS was associated with increased likelihood of BRCA1/2 PV in both DCIS and G1BC, although the 10% threshold was not predictive for G1GB. 13/32 (40.6%) DCIS and 0/17 with G1BC <40 years had a non-BRCA1/2 PV (p<0.001). 0/16 DCIS G1 had a PV. For G2 and G3 DCIS, PV rates were 10/98 (BRCA1/2) and 9/90 (non-BRCA1/2), and 8/47 (BRCA1/2) and 8/45 (non-BRCA1/2), respectively. 6/9 BRCA1 and 3/26 BRCA2-associated DCIS were oestrogen receptor negative-(p=0.003). G1BC population testing showed no increased PV rate (OR=1.16, 95% CI 0.28 to 4.80). Conclusion DCIS is more likely to be associated with both BRCA1/2 and non-BRCA1/2 PVs than G1BC. Extended panel testing ought to be offered in young-onset DCIS where PV detection rates are highest. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. No association between breast pain and breast cancer: a prospective cohort study of 10 830 symptomatic women presenting to a breast cancer diagnostic clinic.
- Author
-
Dave, Rajiv V, Bromley, Hannah, Taxiarchi, Vicky P, Camacho, Elizabeth, Chatterjee, Sumohan, Barnes, Nicola, Hutchison, Gillian, Bishop, Paul, Hamilton, William, Kirwan, Cliona C, and Gandhi, Ashu
- Subjects
BREAST cancer ,CANCER pain ,COHORT analysis ,LONGITUDINAL method ,MEDICAL economics ,BREAST tumor diagnosis ,NATIONAL health services ,COST benefit analysis ,IMPACT of Event Scale ,BREAST tumors ,QUALITY-adjusted life years - Abstract
Background: Women with breast pain constitute >20% of breast clinic attendees.Aim: To investigate breast cancer incidence in women presenting with breast pain and establish the health economics of referring women with breast pain to secondary care.Design and Setting: A prospective cohort study of all consecutive women referred to a breast diagnostic clinic over 12 months.Method: Women were categorised by presentation into four distinct clinical groups and cancer incidence investigated.Results: Of 10 830 women, 1972 (18%) were referred with breast pain, 6708 (62%) with lumps, 480 (4%) with nipple symptoms, 1670 (15%) with 'other' symptoms. Mammography, performed in 1112 women with breast pain, identified cancer in eight (0.7%). Of the 1972 women with breast pain, breast cancer incidence was 0.4% compared with ∼5% in each of the three other clinical groups. Using 'breast lump' as reference, the odds ratio (OR) of women referred with breast pain having breast cancer was 0.05 (95% confidence interval = 0.02 to 0.09, P<0.001). Compared with reassurance in primary care, referral was more costly (net cost £262) without additional health benefits (net quality-adjusted life-year [QALY] loss -0.012). The greatest impact on the incremental cost-effectiveness ratio (ICER) was when QALY loss because of referral-associated anxiety was excluded. Primary care reassurance no longer dominated, but the ICER remained greater (£45 528/QALY) than typical UK National Health Service cost-effectiveness thresholds.Conclusion: This study shows that referring women with breast pain to a breast diagnostic clinic is an inefficient use of limited resources. Alternative management pathways could improve capacity and reduce financial burden. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
16. PRIMUM NON NOCERE: ABEMACICLIB THERAPY USING THE MONARCHE CRITERIA RESULTS IN LARGE NUMBERS OF EXCESS AXILLARY NODE CLEARANCES – TIME TO PAUSE AND REFLECT.
- Author
-
Ahari, Daniel, Wilkinson, Mark, Taxiarchi, Vicky, Ali, Nisha, Dave, Rajiv, and Gandhi, Ashu
- Published
- 2024
- Full Text
- View/download PDF
17. Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers.
- Author
-
Marcinkute, Ruta, Woodward, Emma Roisin, Gandhi, Ashu, Howell, Sacha, Crosbie, Emma J., Wissely, Julie, Harvey, James, Highton, Lindsay, Murphy, John, Holland, Cathrine, Edmondson, Richard, Clayton, Richard, Barr, Lester, Harkness, Elaine F., Howell, Anthony, Lalloo, Fiona, and Evans, D. Gareth
- Abstract
Background Women testing positive for BRCA1/2 pathogenic variants have high lifetime risks of breast cancer (BC) and ovarian cancer. The effectiveness of risk reducing surgery (RRS) has been demonstrated in numerous previous studies. We evaluated long-term uptake, timing and effectiveness of risk reducing mastectomy (RRM) and bilateral salpingo-oophorectomy (RRSO) in healthy BRCA1/2 carriers. Methods Women were prospectively followed up from positive genetic test (GT) result to censor date. 1² testing compared categorical variables; Cox regression model estimated HRs and 95% CI for BC/ovarian cancer cases associated with RRS, and impact on all-cause mortality; Kaplan-Meier curves estimated cumulative RRS uptake. The annual cancer incidence was estimated by women-years at risk. Results In total, 887 women were included in this analysis. Mean follow-up was 6.26 years (range=0.01-24.3; total=4685.4 women-years). RRS was performed in 512 women, 73 before GT. Overall RRM uptake was 57.9% and RRSO uptake was 78.6%. The median time from GT to RRM was 18.4 months, and from GT to RRSO-10.0 months. Annual BC incidence in the study population was 1.28%. Relative BC risk reduction (RRM versus non-RRM) was 94%. Risk reduction of ovarian cancer (RRSO versus non-RRSO) was 100%. Conclusion Over a 24-year period, we observed an increasing number of women opting for RRS. We showed that the timing of RRS remains suboptimal, especially in women undergoing RRSO. Both RRM and RRSO showed a significant effect on relevant cancer risk reduction. However, there was no statistically significant RRSO protective effect on BC. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer.
- Author
-
Evans, D.Gareth, Gandhi, Ashu, Wisely, Julie, Clancy, Tara, Woodward, Emma R., Harvey, James, Highton, Lyndsey, Murphy, John, Barr, Lester, Howell, Sacha J., Lalloo, Fiona, Harkness, Elaine F., and Howell, Anthony
- Subjects
BREAST cancer ,BREAST biopsy ,DISEASE risk factors ,CANCER diagnosis ,COMPETING risks ,ACTIVATED protein C resistance - Abstract
Bilateral-Risk-Reducing-Mastectomy-(BRRM) is well described in BRCA1/2 pathogenic variant carriers. However, little is known about the relative uptake, time trends or factors influencing uptake in those at increased breast cancer risk not known to be carriers. The aim of this study is to assess these factors in both groups. BRRM uptake was assessed from entry to the Manchester Family History Clinic or from date of personal BRCA1/2 test. Follow up was censored at BRRM, breast cancer diagnosis, death or January 01, 2020. Cumulative incidence and cause specific and competing risk regression analyses were used to assess the significance of factors associated with BRRM. Of 7195 women at ≥25% lifetime breast cancer risk followed for up to 32 years, 451 (6.2%) underwent pre-symptomatic BRRM. Of those eligible in different risk groups the 20-year uptake of BRRM was 47.7%-(95%CI = 42.4–53.2%) in 479 BRCA1/2 carriers; 9.0% (95%CI = 7.26–11.24%) in 1261 women at ≥40% lifetime risk (non-BRCA), 4.8%-(95%CI = 3.98–5.73%) in 3561 women at 30–39% risk and 2.9%-(95%CI = 2.09–4.09%) in 1783 women at 25–29% lifetime risk. In cause-specific Cox regression analysis death of a sister with breast cancer<50 (OR = 2.4; 95%CI = 1.7–3.4), mother<60 (OR = 1.9; 95%CI = 1.5–2.3), having children (OR = 1.4; 95%CI = 1.1–1.8), breast biopsy (OR = 1.4; 95%CI = 1.0–1.8) were all independently associated with BRRM uptake, while being older at assessment was less likely to be associated with BRRM (>50; OR = 0.26,95%CI = 0.17–0.41). Uptake continued to rise to 20 years from initial risk assessment. We have identified several additional factors that correlate with BRRM uptake and demonstrate continued increases over time. These factors will help to tailor counselling and support for women. • BRRM continues even 20 years post original breast cancer risk assessment. • Potential triggers include death of mother/sister, children and a breast biopsy. • Uptake is clearly informed by lifetime risk of BC and higher in younger the women. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. No association between breast pain and breast cancer.
- Author
-
Dave, Rajiv V., Bromley, Hannah, Taxiarchi, Vicky P., Camacho, Elizabeth, Chatterjee, Sumohan, Barnes, Nicola, Hutchison, Gillian, Bishop, Paul, Kirwan, Cliona C., and Gandhi, Ashu
- Subjects
CANCER pain ,BREAST cancer - Published
- 2023
- Full Text
- View/download PDF
20. Efficient management of new patient referrals: Further data with increased numbers confirms the safety of advanced nurse practitioner (ANP) led telephone breast pain clinics.
- Author
-
Robinson, Claire, Ellis, Katie, Fatayer, Hiba, Touqan, Nader, and Gandhi, Ashu
- Subjects
PAIN clinics ,NURSE practitioners ,MEDICAL referrals ,TELEPHONES ,TELEPHONE calls - Published
- 2022
- Full Text
- View/download PDF
21. Surgical Outcome Measures in a Cohort of Patients at High Risk of Breast Cancer Treated by Bilateral Risk-Reducing Mastectomy and Breast Reconstruction.
- Author
-
Gandhi, Ashu, Duxbury, Paula, Clancy, Tara, Lalloo, Fiona, Wisely, Julie A., Kirwan, Cliona C., Foden, Philip, Stocking, Katie, Howell, Anthony, and Evans, D. Gareth
- Published
- 2022
- Full Text
- View/download PDF
22. MAMMA (Mastitis And Mammary Abscess Management Audit): Phase 2 outcomes.
- Author
-
Courtney, Alona, Parks, Ruth, Wilkins, Alexander, Brown, Ruth, O'Connell, Rachel, Dave, Rajiv, Dillon, Marianne, Fatayer, Hiba, Gallimore, Rachel, Gandhi, Ashu, Gardiner, Matthew, Harmer, Victoria, Hookway, Lyndsey, Irwin, Gareth, Ives, Charlotte, Mathers, Helen, Murray, Juliette, O'Leary, Peter, Patani, Neill, and Paterson, Sophie
- Subjects
MASTITIS ,ABSCESSES - Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.